Other epidermal disorder

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

4 events
Mar 2025Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Merck Sharp & Dohme LLC — PHASE2

TrialRECRUITING
Jul 2023A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Taiho Oncology, Inc. — PHASE2

TrialRECRUITING
Apr 2023A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

Regor Pharmaceuticals Inc. — PHASE1

TrialACTIVE NOT RECRUITING
Jul 2022Roll-over Study to Allow Continued Access to Ribociclib

Novartis Pharmaceuticals — PHASE4

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Other epidermal disorder.
Check the disease page for updates →

Clinical Trial Landscape

No active clinical trials currently recruiting for Other epidermal disorder.
Search all trials →
Search clinical trials for Other epidermal disorder

Recent News & Research

No recent news articles indexed yet for Other epidermal disorder.
Search PubMed for Other epidermal disorder

Browse all Other epidermal disorder news →

Specialist Network

Top 6 by expertise

View all Other epidermal disorder specialists →

Quick Actions